Proton pump inhibitors alter the composition of the gut microbiota

Matthew A Jackson, Julia K Goodrich, Maria-Emanuela Maxan, Daniel E Freedberg, Julian A Abrams, Angela C Poole, Jessica L Sutter, Daphne Welter, Ruth E Ley, Jordana T Bell, Tim D Spector, Claire J Steves, Matthew A Jackson, Julia K Goodrich, Maria-Emanuela Maxan, Daniel E Freedberg, Julian A Abrams, Angela C Poole, Jessica L Sutter, Daphne Welter, Ruth E Ley, Jordana T Bell, Tim D Spector, Claire J Steves

Abstract

Objective: Proton pump inhibitors (PPIs) are drugs used to suppress gastric acid production and treat GI disorders such as peptic ulcers and gastro-oesophageal reflux. They have been considered low risk, have been widely adopted, and are often over-prescribed. Recent studies have identified an increased risk of enteric and other infections with their use. Small studies have identified possible associations between PPI use and GI microbiota, but this has yet to be carried out on a large population-based cohort.

Design: We investigated the association between PPI usage and the gut microbiome using 16S ribosomal RNA amplification from faecal samples of 1827 healthy twins, replicating results within unpublished data from an interventional study.

Results: We identified a significantly lower abundance in gut commensals and lower microbial diversity in PPI users, with an associated significant increase in the abundance of oral and upper GI tract commensals. In particular, significant increases were observed in Streptococcaceae. These associations were replicated in an independent interventional study and in a paired analysis between 70 monozygotic twin pairs who were discordant for PPI use. We propose that the observed changes result from the removal of the low pH barrier between upper GI tract bacteria and the lower gut.

Conclusions: Our findings describe a significant impact of PPIs on the gut microbiome and should caution over-use of PPIs, and warrant further investigation into the mechanisms and their clinical consequences.

Keywords: GASTRIC ACID; INTESTINAL MICROBIOLOGY; LACTIC ACID BACTERIA; LACTOBACILLUS; PROTON PUMP INHIBITION.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Distributions of covariates included for analysis, compared between proton pump inhibitor (PPI) users and non-users. Wilcoxon rank sum tests were carried out to compare the distribution of covariates in the modelling analysis. All variables were on a different scale so were centred and scaled before plotting. PPI users were older, frailer, had higher body mass index (BMI) and lower scores on the high alcohol food frequency questionnaire (FFQ) principle component (PC). Significant differences are indicated where ***p

Figure 2

Comparison of α diversity in…

Figure 2

Comparison of α diversity in proton pump inhibitor (PPI) users and non-users, and…

Figure 2
Comparison of α diversity in proton pump inhibitor (PPI) users and non-users, and in individuals with and without GI indications. Four metrics of α diversity were calculated on rarefied samples and one-tailed Wilcoxon rank sum tests carried out to test for significantly lower diversity with PPI use, or with GI indication. Significantly lower diversity was observed for all metrics in PPI users versus non-users (*); no difference was found splitting by GI indication (NS).

Figure 3

Summary of taxonomic associations with…

Figure 3

Summary of taxonomic associations with proton pump inhibitor (PPI) use. Shown are all…

Figure 3
Summary of taxonomic associations with proton pump inhibitor (PPI) use. Shown are all collapsed groups used in taxonomic association analyses that had complete taxonomic assignment (not including collapsed species). Connecting lines highlight the taxonomic relationships between groups (not considering genetic relatedness). Taxa significantly associated with PPI use are highlighted with circles, larger circles representing a larger absolute coefficient of association. Association analyses were carried out at each taxonomic level independently. Taxa at higher abundance with PPI use are shown in blue and at lower abundance in red. Lines connecting taxa of similar association are also coloured and weighted by the average coefficient between the taxa. Names are shown for significant results only. Those in bold retained significance between 70 discordant monozygotic (MZ) twins, and underlined taxa replicated in analysis of interventional study data.

Figure 4

Paired plots of the relative…

Figure 4

Paired plots of the relative abundances of Streptococcaceae and Lactobacillales within monozygotic (MZ)…

Figure 4
Paired plots of the relative abundances of Streptococcaceae and Lactobacillales within monozygotic (MZ) twins discordant for proton pump inhibitor (PPI) use. These were the only collapsed family and order traits found to be significantly different in discordant MZ twin pairs, both higher in abundance in PPI users.
Figure 2
Figure 2
Comparison of α diversity in proton pump inhibitor (PPI) users and non-users, and in individuals with and without GI indications. Four metrics of α diversity were calculated on rarefied samples and one-tailed Wilcoxon rank sum tests carried out to test for significantly lower diversity with PPI use, or with GI indication. Significantly lower diversity was observed for all metrics in PPI users versus non-users (*); no difference was found splitting by GI indication (NS).
Figure 3
Figure 3
Summary of taxonomic associations with proton pump inhibitor (PPI) use. Shown are all collapsed groups used in taxonomic association analyses that had complete taxonomic assignment (not including collapsed species). Connecting lines highlight the taxonomic relationships between groups (not considering genetic relatedness). Taxa significantly associated with PPI use are highlighted with circles, larger circles representing a larger absolute coefficient of association. Association analyses were carried out at each taxonomic level independently. Taxa at higher abundance with PPI use are shown in blue and at lower abundance in red. Lines connecting taxa of similar association are also coloured and weighted by the average coefficient between the taxa. Names are shown for significant results only. Those in bold retained significance between 70 discordant monozygotic (MZ) twins, and underlined taxa replicated in analysis of interventional study data.
Figure 4
Figure 4
Paired plots of the relative abundances of Streptococcaceae and Lactobacillales within monozygotic (MZ) twins discordant for proton pump inhibitor (PPI) use. These were the only collapsed family and order traits found to be significantly different in discordant MZ twin pairs, both higher in abundance in PPI users.

References

    1. Katelaris PH. Proton pump inhibitors. Med J Aust 1998;169:208–11.
    1. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. . Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677–86. 10.1111/j.1365-2036.2005.02391.x
    1. Sharma VK, Leontadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001;15:227–31. 10.1046/j.1365-2036.2001.00904.x
    1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200. 10.1111/j.1572-0241.2005.41217.x
    1. Yachimski PS, Farrell EA, Hunt DP, et al. . Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med 2010;170:779–83. 10.1001/archinternmed.2010.51
    1. Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005;59:1210–17. 10.1111/j.1368-5031.2005.00660.x
    1. Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. Ann Pharmacother 2002;36:1929–37. 10.1345/aph.1C151
    1. National Institute for Health and Clinical Excellence. NSAIDs—prescribing issues 2015. (accessed 5 Jul 2015).
    1. IMS Health Top-Line Market Data 2014. (accessed 6 Jul 2015).
    1. Akram F, Huang Y, Lim V, et al. . Proton pump inhibitors: are we still prescribing them without valid indications? Australas Med J 2014;7:465–70. 10.4066/AMJ.2014.2093
    1. Eid SM, Boueiz A, Paranji S, et al. . Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561–8. 10.2169/internalmedicine.49.4064
    1. Heidelbaugh JJ, Kim AH, Chang R, et al. . Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 2012;5:219–32. 10.1177/1756283X12437358
    1. Fitton A, Wiseman L. Pantoprazole. Drugs 1996;51:460–82. 10.2165/00003495-199651030-00012
    1. Wilde MI, McTavish D. Omeprazole. Drugs 1994;48:91–132. 10.2165/00003495-199448010-00008
    1. Langtry HD, Wilde MI. Lansoprazole. Drugs 1997;54:473–500. 10.2165/00003495-199754030-00010
    1. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422–8. 10.1016/j.jclinepi.2003.08.015
    1. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047–56. 10.1111/j.1572-0241.2007.01275.x
    1. Laheij RJF, Sturkenboom MCJM, Hassing, et al. . Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292:1955–60. 10.1001/jama.292.16.1955
    1. Xu HB, Wang HD, Li CH, et al. . Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res 2015;14:7490–501. 10.4238/2015.July.3.25
    1. Janarthanan S, Ditah I, Adler DG, et al. . Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001–10. 10.1038/ajg.2012.179
    1. Kwok CS, Arthur AK, Anibueze CI, et al. . Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011–19. 10.1038/ajg.2012.108
    1. Faust K, Sathirapongsasuti JF, Izard J, et al. . Microbial co-occurrence relationships in the Human Microbiome. PLoS Comput Biol 2012;8:e1002606 10.1371/journal.pcbi.1002606
    1. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207–14. 10.1038/nature11234
    1. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. . A core gut microbiome in obese and lean twins. Nature 2009;457:480–4. 10.1038/nature07540
    1. Willing BP, Dicksved J, Halfvarson J, et al. . A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010;139:1844–54.e1. 10.1053/j.gastro.2010.08.049
    1. Claesson MJ, Jeffery IB, Conde S, et al. . Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178–84. 10.1038/nature11319
    1. Owens RC, Donskey CJ, Gaynes RP, et al. . Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46(Suppl 1):S19–31. 10.1086/521859
    1. Tsuda A, Suda W, Morita H, et al. . Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol 2015;6:e89 10.1038/ctg.2015.20
    1. Amir I, Konikoff FM, Oppenheim M, et al. . Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol 2014;16:2905–14. 10.1111/1462-2920.12285
    1. Rosen R, Hu L, Amirault J, et al. . 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr 2015;166:917–23. 10.1016/j.jpeds.2014.12.067
    1. Freedberg DE, Toussaint NC, Chen SP, et al. . Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015;149:883–885.e9. 10.1053/j.gastro.2015.06.043
    1. Seto CT, Jeraldo P, Orenstein R, et al. . Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014;2:42 10.1186/2049-2618-2-42
    1. Goodrich JK, Waters JL, Poole AC, et al. . Human genetics shape the gut microbiome. Cell 2014;159:789–99. 10.1016/j.cell.2014.09.053
    1. Caporaso JG, Kuczynski J, Stombaugh J, et al. . QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010;7:335–6. 10.1038/nmeth.f.303
    1. Moayyeri A, Hammond CJ, Valdes AM, et al. . Cohort profile: TwinsUK and healthy ageing twin study. Int J Epidemiol 2013;42:76–85. 10.1093/ije/dyr207
    1. Teucher B, Skinner J, Skidmore PML, et al. . Dietary patterns and heritability of food choice in a UK female twin cohort. Twin Res Hum Genet 2007;10:734–48. 10.1375/twin.10.5.734
    1. Searle SD, Mitnitski A, Gahbauer EA, et al. . A standard procedure for creating a frailty index. BMC Geriatr 2008;8:24 10.1186/1471-2318-8-24
    1. Bates D, Mächler M, Bolker BM, et al. . Fitting linear mixed-effects models using lme4. ArXIV e-print; Press J Stat Softw 2015;67:1–48.
    1. Dabney A, Storey JD. qvalue: Q-value estimation for false discovery rate control. R package version 2.2.0 2015
    1. Jakobsson HE, Jernberg C, Andersson AF, et al. . Short-term antibiotic treatment has differing long- term impacts on the human throat and gut microbiome. PLoS ONE 2010;5:e9836 10.1371/journal.pone.0009836
    1. Hirai M, Asuma T, Ito S, et al. . A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995;30:461–4. 10.1007/BF02347561
    1. Nagata K, Satoh H, Iwahi T, et al. . Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother 1993;37:769–74. 10.1128/AAC.37.4.769
    1. Ajdić D, McShan WM, McLaughlin RE, et al. . Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci USA 2002;99:14434–9. 10.1073/pnas.172501299
    1. Longo DL, Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015;372:1539–48. 10.1056/NEJMra1403772
    1. Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio 2015;6:e00974 10.1128/mBio.00974-15
    1. de Jager CPC, Wever PC, Gemen EFA, et al. . Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012;36:941–9. 10.1111/apt.12069
    1. Dumoulin G. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. Lancet 1982;319:242–5. 10.1016/S0140-6736(82)90974-6
    1. Schuijt T, Lankelma J, Scicluna BP, et al. . The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 2016;65: 575–83.. 10.1136/gutjnl-2015-309728

Source: PubMed

3
Prenumerera